Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2.

ingentiumby ingentium

In Antibodies Literature.

Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2.

Publication date: Jul 19, 2024

Antibodies play a pivotal role in protecting from SARS-CoV-2 infection, but their efficacy is challenged by the continuous emergence of viral variants. In this study, we describe two broadly neutralizing antibodies cloned from the memory B cells of a single convalescent individual after infection with ancestral SARS-CoV-2. Cv2. 3194, a resilient class 1 anti-RBD antibody, remains active against Omicron sub-variants up to BA. 2.86. Cv2. 3132, a near pan-Sarbecovirus neutralizer, targets the heptad repeat 2 membrane proximal region. When combined, Cv2. 3194 and Cv2. 3132 form a complementary SARS-CoV-2 neutralizing antibody cocktail exhibiting a local dose-dependent synergy. Thus, remarkably robust neutralizing memory B cell antibodies elicited in response to ancestral SARS-CoV-2 infection can withstand viral evolution and immune escape. The cooperative effect of such antibody combination may confer a certain level of protection against the latest SARS-CoV-2 variants.

Open Access PDF

Concepts Keywords
Antibodies immunology
Cocktail virology
Latest
Resilient

Semantics

Type Source Name
disease IDO cell
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH infection
disease VO dose
drug DRUGBANK Hydroxycitronellal
drug DRUGBANK Methylergometrine
disease VO vaccinated
disease MESH re infection
disease VO Glycoprotein
drug DRUGBANK Angiotensin II
disease VO population
drug DRUGBANK Diethylstilbestrol
disease IDO assay
disease VO injection
disease MESH weight loss
disease VO URE
drug DRUGBANK Succimer
disease VO frequency
drug DRUGBANK Coenzyme M
drug DRUGBANK Histidine
disease IDO acute infection
disease MESH clonal evolution
disease VO vaccination
disease MESH convalescence
disease VO effective
disease MESH emergency
disease IDO process
disease VO immunized
drug DRUGBANK Amlodipine
disease IDO facility
drug DRUGBANK Etoperidone
drug DRUGBANK Esomeprazole
drug DRUGBANK Aminosalicylic Acid
disease VO company
disease MESH immunocompromised patients
disease MESH breakthrough infection
disease MESH AIDS
drug DRUGBANK Carboxyamidotriazole
disease IDO production
drug DRUGBANK Efavirenz
drug DRUGBANK Tricyclazole
drug DRUGBANK Immune Globulin Human
disease VO efficiency
disease VO dead
disease IDO site
drug DRUGBANK Silver
drug DRUGBANK Titanium
disease VO device
disease VO publication
disease VO manufacturer
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Puromycin
disease IDO quality
drug DRUGBANK Edetic Acid
disease VO viability
disease VO time
disease MESH dissociation
drug DRUGBANK Dextran

Original Article

(Visited 2 times, 1 visits today)